Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib and Alpelisib in HRAS-overexpressing and/or PIK3CA-mutated/Amplified Recurrent/Metastatic HNSCC
NCT04997902Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- Dec 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib, alpelisib in head and neck squamous cell carcinoma (HNSCC), sponsored by Kura Oncology. Started Dec 2021; status: completed.
02
Drugs
tipifarnibalpelisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04997902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997902.